Objective. We estimated the prevalence of preventive aspirin and/or other antiplatelet medication use and the dosage of aspirin use in the U.S. adult population.
Heart attacks and strokes are the leading causes of mortality among U.S. adults, and antiplatelet therapy is one of the preventive strategies recommended to reduce the risk of atherosclerotic cardiovascular events. [1] [2] [3] Aspirin, one of the oldest and least expensive medications, was initially used as an analgesic and antipyretic drug before its anti-inflammatory properties were discovered. 4 More recently, the ability of low-dose aspirin to inhibit platelet aggregation and prevent thrombotic cardiovascular events has made it a key instrument in the prevention of heart attacks and strokes. [5] [6] [7] The U.S. Food and Drug Administration has approved professional labeling indications for preventive aspirin use in patients with prior myocardial infarction, unstable angina, and transient ischemic attacks. 8 Taking low-dose aspirin to prevent the first occurrence of heart attack or ischemic stroke in people where the expected benefit outweighs the risk of harm has been recommended by the medical communities, including the American Heart Association, the American Stroke Association, the American College of Cardiology Foundation, the American Diabetes Association, and the U.S. Preventive Services Task Force (USPSTF). [9] [10] [11] [12] [13] In 2011, the U.S. Department of Health and Human Services launched the Million Hearts™ initiative, a multifaceted strategy of evidence-based interventions aimed at preventing one million heart attacks and strokes by 2016. 14 Increasing preventive aspirin use among people who are at high risk for cardiovascular disease (CVD) in the U.S. adult population is a key component of the Million Hearts initiative. 15 Monitoring the U.S. prevalence of preventive aspirin and/or other antiplatelet medication use is essential to assess adherence to current evidence-based national guidelines and to provide surveillance on the nation's progress toward preventive treatment goals. Existing sources of data for the United States include the National Ambulatory Medical Care Survey, the National Hospital Ambulatory Medical Care Survey, 1, 16 the Behavioral Risk Factor Surveillance System, 17, 18 the Medical Expenditure Panel Survey, 19 and the National Health Interview Survey. 20 In 2011-2012, the National Health and Nutrition Examination Survey (NHANES) fielded a detailed preventive aspirin use questionnaire designed to provide improved prevalence estimates of preventive aspirin use. The initial reports based on the NHANES 2011-2012 preventive aspirin use data were recently published. 21, 22 These reports provide basic descriptive data on physician recommendation and patient adherence rates for primary and secondary preventive aspirin use in the United States, a multivariate model analysis of factors influencing the likelihood of physician recommendation and patient adherence, and an analysis of the frequency of clinician aspirin recommendations for preventive aspirin use among those eligible according to current guidelines.
Our report supplements these earlier works by presenting additional new information: the first population prevalence estimates for overall preventive aspirin and/or other antiplatelet medication use in the United States by demographic subgroups and key health conditions, more detailed descriptive statistics for primary and secondary preventive aspirin use, and the first U.S. national-level data on the distribution of preventive aspirin use frequency and daily dosages. These data are central to public health planning for optimizing preventive aspirin use in the United States and to help monitor progress toward meeting current public health objectives.
METHODS
NHANES is a continuous, cross-sectional, nationally representative survey conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. A complex, multistage probability sampling design is used to generate a representative sample of the civilian, noninstitutionalized U.S. population of all ages. Participants receive a detailed in-person interview in their home, followed by a physical examination at a mobile examination center. Data from the 2011-2012 survey were used with an overall interview response rate of 73%. 23 The final sample for this report included 3,599 adults aged 40 years, after excluding four interviewed people who did not have preventive aspirin use questionnaire data.
Trained interviewers obtained preventive aspirin use data as part of the NHANES ongoing prescription medication data collection. During the in-person interview, participants aged 40 years were asked, "Doctors and other health-care providers sometimes recommend that you take a low-dose aspirin each day to prevent heart attacks, strokes, or cancer. Have you ever been told to do this?" 24 Those who answered "yes" were then asked, "Are you now following this advice?" Participants responding "yes" or "sometimes" were considered as medically recommended preventive aspirin users. Participants responding "yes," "sometimes," or "stopped aspirin use due to side effects" were considered as adherent to medical recommendations. Those who answered "no" to the first question were asked, "On your own, are you now taking a low-dose aspirin each day to prevent heart attack, strokes, or cancer?" A "yes" answer was classified as self-initiated aspirin use. Overall current preventive aspirin use combines those who indicated medically recommended or self-initiated preventive aspirin use. The preventive aspirin use questionnaire administration and study definitions are summarized ( Figure 1 ).
The frequency of preventive aspirin use and the strength of the aspirin pill taken were collected for all current preventive aspirin users. Frequency of use was recoded into three groups: one every day, one every other day, and all other frequencies of use.
Antiplatelet agents including clopidogrel, prasugrel, cilostazol, ticlopidine, and a combination drug of aspirin and dipyridamole were identified from NHANES 2011-2012 prescription medication data. Those who reported taking preventive aspirin and/or prescription antiplatelet medication were considered antiplatelet medication users.
During the household interview, data were also collected on age, sex, race/Hispanic origin, health insurance, number of health-care provider visits in the past year, smoking status, and doctor-diagnosed health conditions including arthritis, diabetes, hyper-tension, high cholesterol, heart attack, coronary heart disease (CHD), angina pectoris, and stroke. CVD was defined as a history of a medical diagnosis of heart attack, CHD, angina pectoris, and/or stroke. Aspirin use among those with CVD was considered secondary prevention, and aspirin use among those without CVD was considered primary prevention.
For those without CVD, the 10-year general CVD risk scores were calculated using sex-specific prediction equations from the Framingham Heart Study. 25 The predictors included age, diabetes, smoking, mean systolic blood pressure (whether treated or untreated), total cholesterol, and high-density lipid cholesterol. The algorithms were for individuals aged 30-74 years. NHANES participants aged 75 years were considered as 74 years of age for the risk score calculation. CVD risk scores were stratified into three groups: high risk (scores 10%), moderate risk (scores 5%-10%), and low risk (scores 5%). The CVD definition, CVD risk categories, and sample sizes are illustrated ( Figure 2 ). In addition, the USPSTF-recommended algorithms were used to calculate the 10-year CHD risk for men aged 45-79 years 13, 26 and the 10-year stroke risk for women aged 55-79 years. 13, 27 However, atrial fibrillation and left ventricular hypertrophy were not accounted for in the stroke risk calculation for women due to the lack of data in NHANES. The USPSTF-recommended age-and sex-specific risk levels were used to identify those most likely to benefit from primary preventive aspirin use (at CHD risk 4%, 9%, and 12% for men aged 45-59, 60-69, and 70-79 years, respectively; and at stroke risk 3%, 8%, and 11% for women aged 55-59, 60-69, and 70-79 years, respectively). 13 We used SAS ® version 9.3 28 and SUDAAN ® version 11.0 29 to conduct statistical analyses. Sampling weights were used to adjust for nonresponse, noncoverage, and differential probabilities of selection. Variance estimates were computed with Taylor series linearization to account for the complex sample design. The reliability of estimates was evaluated using the relative standard error (RSE) and minimum sample size criteria. NHANES recommends that an estimate with an RSE 30% be considered potentially unreliable. 30 Minimum sample sizes were computed by average design effects and specified proportions. 31 Estimates not meeting standards for RSE or minimum sample size are noted in the tables. Statistical hypotheses were tested with a two-sided t-test at the 0.05 significance level. Bonferroni correction was used for six multiple comparisons among race and Hispanic origin subgroups. The linear trends test across age groups used orthogonal polynomial contrasts. Probability values of 0.05 were considered significant.
RESULTS

Overall preventive aspirin and/or other antiplatelet medication use
One-third (33%) of U.S. adults aged 40 years were currently taking preventive aspirin and/or other antiplatelet medications (Table 1) . Specifically, 29% reported taking aspirin, 3% reported taking both aspirin and other antiplatelet medications, and 1% reported taking other antiplatelet medications. Preventive aspirin use increased with age (from 11% among those aged 40-49 years to 54% among those aged 80 years, p0.001). Population subgroups significantly more likely to take preventive aspirin were men vs. women, non-Hispanic white or black adults vs. non-Hispanic Asian or Hispanic adults, those with health insurance vs. those without health insurance, adults who had 2 doctor visits in the preceding year vs. those who had 0-1 doctor visit in the preceding year, and those with arthritis vs. those without arthritis. Preventive aspirin use prevalence doubled among those with diabetes, hypertension, or high cholesterol compared with those who did not have these conditions. Compared with nonsmokers, smokers were less likely to take preventive aspirin ( Table 1) .
Medically recommended preventive aspirin use prevalence was 28%, which constituted 86% of overall preventive aspirin use. As a consequence, the patterns of overall preventive aspirin use and of medically recommended preventive aspirin use in specific demographic subgroups were similar. About 5% of U.S. adults reported taking preventive aspirin on their own. Self-initiated preventive aspirin use was significantly higher among men than women (6% vs. 3%, p0.032) ( Table 1) .
About 82% of those who had ever been told by a doctor to take preventive aspirin were following this advice (80% were currently taking it and 2% had stopped aspirin use due to its side effects). Adherence rates increased with age, from 61% among those aged 40-49 years to 89% among those aged 80 years. People with health insurance were more likely than those without health insurance to follow their doctors' advice ( Table 1) .
Aspirin and/or other antiplatelet medication use for secondary prevention
The prevalence of preventive aspirin and/or other antiplatelet medication use for secondary prevention was 76% (Table 2) , including 52% taking aspirin, 16% taking both aspirin and other antiplatelet medications, and 8% taking other antiplatelet medications. Preventive aspirin and/or other antiplatelet medication use prevalences for secondary prevention were similar across almost all demographic and CVD risk factor subgroups, with the exception of cholesterol status. Preventive aspirin use prevalences for secondary prevention were 53% among those with a history of stroke and 77% among those with a history of heart attack ( Table 2) .
Among individuals with CVD who had ever been told by a doctor to take preventive aspirin, 91% were currently following this advice ( Table 2) . We found no significant differences in adherence rates for secondary prevention aspirin use in any subgroups examined. The adherence rates were 95% for those with a history of heart attack and 85% for those with a history of stroke.
Aspirin use for primary prevention
The prevalence of preventive aspirin use for primary prevention was 28% (Table 3 ). Primary aspirin use increased with age (from 9% among those aged 40-49 years to 51% among those aged 80 years, p0.001). Subpopulations significantly more likely to take aspirin for primary prevention included non-Hispanic white or black people vs. non-Hispanic Asian or Hispanic adults, those with health insurance vs. those without health insurance, those with 2 doctor visits per year vs. those with 0-1 doctor visit per year, and those with arthritis vs. those without arthritis. Aspirin use doubled among those with significant CVD risk factors, such as diabetes, hypertension, or high cholesterol, compared with those without such conditions (Table 3) .
Preventive aspirin use increased from 8% among those with a low CVD risk to 24% among those with a moderate CVD risk to 41% among those with a high CVD risk (Table 3 ). Medically recommended use accounted for 79%, 78%, and 83% of those with a low, moderate, and high risk of CVD, respectively. Using the USPSTF-recommended CHD and stroke risk assessment approaches, prevalence of preventive aspirin use was 32% among men aged 45-79 years without CVD but at high CHD risk and 47% among women without CVD but at high stroke risk. An estimated 79% of those without CVD who had ever been told by a doctor to take preventive aspirin were following this advice. Adherence rates for primary prevention increased with age, from 56% among those aged 40-49 years to 88% among those aged 80 years (p0.001). Adults with health insurance were more likely than those without health insurance to follow their doctor's advice (80% vs. 63%, p0.008). Smokers were less likely than nonsmokers to follow their doctors' advice (66% vs. 80%, p0.027) ( Table 3) .
Current aspirin use patterns and daily dosages
Among current preventive aspirin users, 91% were taking either one aspirin every day (84%) or one aspirin every other day (7%) ( Table 4 ); 9% of current preventive aspirin users took preventive aspirin at other frequencies. Population subgroups significantly more likely to take one aspirin every day were older adults and those with CVD. Also, 87% of medically recommended aspirin users and 67% of self-initiated aspirin users were taking one aspirin every day, while 12% of self-initiated aspirin users were taking one aspirin every other day (Table 4 ).
Among current preventive aspirin users, nearly 70% were taking 81 milligrams (mg) of aspirin daily and 13% were taking 325 mg of aspirin daily (Table  4 ). Another 17% were taking other daily dosages. The percentage of people taking 81 mg of aspirin daily was higher among older adults vs. middle-aged adults, among women vs. men, among those with hypertension vs. without hypertension, and among medically recommended users vs. self-initiated users. The percentages of those taking 325 mg of aspirin daily doubled among men and those with diabetes or CVD compared with women and those without diabetes or CVD, respectively (Table 4 ). 
DISCUSSION
During 2011-2012, one-third of Americans 40 years of age were currently taking preventive aspirin and/or other antiplatelet medications, of whom 97% were tak-ing preventive aspirin. Those who had health insurance or reported 2 doctor visits in the past year were twice as likely to take preventive aspirin as those who did not have either health insurance or 2 doctor visits in the past year. Preventive aspirin use increased with age. (6, 19) 7 (4, 11) 3 a 8 (6, 11) Men were more likely than women to take preventive aspirin, especially when taking it on their own. Similar to other studies, 18, 19, 32 there were significant differences in preventive aspirin use: non-Hispanic white people had the highest use whereas non-Hispanic Asian and Hispanic adults had the lowest preventive aspirin use. Preventive aspirin use prevalence doubled among those with diagnosed diabetes, hypertension, or high cholesterol compared with those who did not have these conditions. However, smokers were less likely than nonsmokers to take preventive aspirin.
A health-care provider's advice to take preventive aspirin appeared to be a strong influence on current preventive aspirin use: overall, nearly 82% of adults who were told to take preventive aspirin reported following this advice. Adherence rates increased with age. Those with health insurance were more adherent to medical advice about preventive aspirin use than those without health insurance. Furthermore, our data appear to show that low-dose preventive aspirin use is generally well tolerated by most people: 2% had stopped recommended preventive aspirin use due to its side effects. Overall, 1% of adults were taking only other prescription antiplatelet medications. However, it is also possible that health-care providers may have already screened out patients at risk of side effects with aspirin therapy; as such, these cases would not be identified in our data.
Antiplatelet therapy is recommended for secondary prevention of cardiovascular events. 2, 3, 33, 34 More than two-thirds of Americans 40 years of age with a diagnosis of CVD reported taking preventive aspirin, and another 8% reported taking only other prescription antiplatelet medications. Health-care provider communication with patients may be a key factor affecting preventive aspirin use. Here, overall adherence rates were extremely high (91%) and there were few disparities in aspirin use by demographic group or comorbid chronic medical conditions. Aspirin use for patients with a history of stroke was lower than for those with a history of CHD. This finding was partly due to the fact that history of ischemic stroke and hemorrhagic stroke cannot be separated in NHANES. An estimated 70% of adults aged 40 years with a diagnosed CVD were taking low-dose aspirin to prevent or control heart disease based on 2012 National Health Interview Survey data. 35 Other previous national estimates of aspirin use among those with CVD were 83% in 2003 Behavioral Risk Factor Surveillance System data, 17 54% in 2005 Medical Expenditure Panel Survey data, 19 and 47% (for use of aspirin and other antiplatelet medications prescribed at outpatient visits) in 2007-2008 National Ambulatory Medical Care Survey/National Hospital Ambulatory Medical Care Survey data. 16 Differences in survey methodologies, study objectives, target populations, and CVD definitions might explain these differences in aspirin use prevalence. Also, wide availability of over-the-counter aspirin and multiple indications for aspirin use make it difficult to compare aspirin use at a person level with aspirin prescribed at the patient visit as in the National Ambulatory Medical Care Survey/National Hospital Ambulatory Medical Care Survey report.
Evidence of the benefits of aspirin for primary CVD prevention is less clear than its benefits for secondary CVD prevention. Currently, the U.S. Food and Drug Administration does not support the use of aspirin for primary prevention. 36 Our data show that 28% of U.S. adults aged 40 years without a history of CVD take preventive aspirin for primary prevention. The demographic and health-care access and utilization profile for primary prevention aspirin use is remarkably similar to that observed for overall preventive aspirin use. And the great majority of people using aspirin for primary prevention were doing so on a doctor's recommendation.
The American Heart Association and American Stroke Association recommend low-dose aspirin use for people at high CVD risk [9] [10] [11] and the American Diabetes Association recommends aspirin use for adults with diabetes at high CVD risk. 12, 37, 38 The USPSTF recommends aspirin use for men aged 45-79 years to prevent myocardial infarction and women aged 55-79 years to prevent ischemic strokes when the aspirin benefits outweigh potential harm due to gastrointestinal hemorrhage. 13 Data from the Multi-Ethnic Study of Atherosclerosis have shown an increased prevalence of primary prevention aspirin use, from 27% at baseline (2000) (2001) (2002) to 44% at follow-up (2005-2007) among those with a Framingham risk score 10%. 30 Our data show that among U.S. men aged 45-79 years and U.S. women aged 55-79 years with cardiovascular risk levels at which CVD events prevented exceeded gastrointestinal harm, only 32% and 47% of men and women, respectively, reported taking aspirin for primary prevention. However, more than half of adults aged 80 years reported taking aspirin for primary prevention even though there is no recommendation for this group in the current USPSTF guidelines.
There is no universal agreement about an optimal aspirin dose for CVD prevention. Clinical and primary prevention trials have demonstrated efficacy for a variety of low-dose aspirin regimens. 39, 40 Taking 75-162 mg of aspirin daily is usually recommended for primary and secondary prevention of CVD. 2, 3, 9, 10, 37 We found that 70% of current aspirin users were taking 81 mg of aspirin daily and 13% were taking 325 mg of aspirin daily. Men vs. women and adults with diagnosed diabetes or CVD vs. without diagnosed diabetes or CVD were more likely to take 325 mg of aspirin daily. Older adults vs. middle-aged adults, women vs. men, those with hypertension vs. without hypertension, and medically recommended users vs. self-initiated users were more likely to take 81 mg of aspirin daily.
Strengths and limitations
This study had several strengths and limitations. NHANES is a nationally representative in-person survey that uses standardized data collection protocols. The cross-sectional survey design is ideal for prevalence estimation; however, two risk factors, history of atrial fibrillation and left ventricular hypertrophy, were not collected in NHANES. Therefore, misclassification is possible in the stroke risk assessment for women. Primarily, we used the sex-specific prediction equations from the Framingham Heart Study to estimate the 10-year general CVD risk scores. Preventive aspirin use data are collected by trained interviewers as part of the NHANES prescription medication data collection; however, self-reported aspirin use and dosage information were not verified by examining the containers. In addition, a detailed clinical history of all past preventive aspirin use and the reasons for stopping aspirin therapy were not captured. Aspirin use for primary prevention needs to balance the risk of bleeding against the benefit of cardio protection; however, NHANES data for severe liver or kidney disease and concurrent use of other medications that might increase the risk of bleeding were not assessed.
CONCLUSION
This study provides national estimates on current preventive aspirin and/or other antiplatelet medication use to help monitor progress toward meeting current public health recommendations. While other alternative antiplatelet medications exist, the vast majority of antiplatelet therapy is with aspirin. Preventive aspirin use in adults at increased risk of CVD remains suboptimal, and disparities in preventive aspirin use in specific demographic subgroups persist. Importantly, a health-care provider's recommendation to take preventive aspirin appears to be a key determinant of current preventive aspirin use.
